Holen Sie sich die Stockscreener-App
6.48
0.93%
0.06
Handel nachbörslich:
6.56
0.08
+1.23%
Schlusskurs vom Vortag:
$6.42
Offen:
$6.66
24-Stunden-Volumen:
371.55K
Relative Volume:
8.45
Marktkapitalisierung:
$562.96M
Einnahmen:
$197.44M
Nettoeinkommen (Verlust:
$-114.14M
KGV:
-4.7265
EPS:
-1.371
Netto-Cashflow:
$-40.20M
1W Leistung:
-42.09%
1M Leistung:
-43.21%
6M Leistung:
-34.87%
1J Leistung:
-8.35%
1-Tages-Spanne:
$6.42
$6.79
1-Wochen-Bereich:
$6.3501
$10.90
52-Wochen-Spanne:
$5.4289
$12.25
Valneva Se Adr Stock (VALN) Company Profile
Compare VALN vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VALN
Valneva Se Adr
|
6.48 | 557.75M | 197.44M | -114.14M | -40.20M | -1.371 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Valneva Se Adr Stock (VALN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-08-03 | Eingeleitet | H.C. Wainwright | Buy |
Valneva Se Adr Aktie (VALN) Neueste Nachrichten
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Valneva SE – VALN - FinancialContent
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study - Yahoo Finance
VALN Shares Plunge Following Uncertain Outcomes in Lyme Disease Vaccine Trial - Bitget
Jefferies reiterates Valneva stock Buy rating after Lyme trial data - Investing.com
Valneva (NASDAQ:VALN) Sees Large Volume IncreaseHere's Why - MarketBeat
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive - Benzinga
HC Wainwright Has Positive Forecast for Valneva Q3 Earnings - MarketBeat
Valneva (NASDAQ:VALN) Shares Gap Down – Here’s Why - Defense World
FY2030 Earnings Forecast for Valneva Issued By HC Wainwright - Defense World
Valneva (NASDAQ:VALN) Shares Gap DownHere's What Happened - MarketBeat
FY2030 Earnings Estimate for Valneva Issued By HC Wainwright - MarketBeat
Valneva (NASDAQ:VALN) Shares Gap UpStill a Buy? - MarketBeat
Earnings call transcript: Valneva SE Q4 2025 sees EPS beat, stock rises - Investing.com Canada
[20-F] Valneva SE Files Annual R... | VALN SEC FilingForm 20-F - Stock Titan
Valneva SE earnings beat by $0.13, revenue topped estimates - Investing.com India
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study - MSN
Valneva (NASDAQ:VALN) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Valneva (NASDAQ:VALN) Trading Up 7.1%Here's What Happened - MarketBeat
Valneva (NASDAQ:VALN) Stock Price Down 5.6%Here's What Happened - MarketBeat
Valneva stock falls after withdrawing chikungunya vaccine BLA in U.S. By Investing.com - Investing.com Nigeria
Valneva stock falls after withdrawing chikungunya vaccine BLA in U.S. - Investing.com
Wise and Virbac Benefit from Quarterly Results, Valneva and Logitech Slide - marketscreener.com
VLA Stock Price and Chart — EURONEXT:VLA - TradingView — Track All Markets
Valneva (NASDAQ:VALN) Shares Up 4.9%What's Next? - MarketBeat
Valneva (NASDAQ:VALN) Stock Price Down 4.6%Time to Sell? - MarketBeat
Valneva (NASDAQ:VALN) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Frazier Life Sciences Management L.P. Makes New Investment in Valneva SE Sponsored ADR $VALN - MarketBeat
Valneva stock rises after positive final Phase 2 results for chikungunya vaccine - Investing.com India
Valneva (NASDAQ:VALN) Stock Price Down 3.1%What's Next? - MarketBeat
Valneva stock rises after positive Lyme disease vaccine booster data - Investing.com
Valneva SE earnings beat by $0.02, revenue fell short of estimates - Investing.com
Valneva (VALN) Projected to Post Earnings on Thursday - MarketBeat
Disney, Brookfield, Nu Holdings and more set to report earnings Thursday - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SEVALN - 2822news.com
Free cash flow per share of Valneva SE Sponsored ADR – LS:A3CPD1 - TradingView
Finanzdaten der Valneva Se Adr-Aktie (VALN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):